Contrasting C4 Therapeutics (CCCC) and The Competition

C4 Therapeutics (NASDAQ:CCCC) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare C4 Therapeutics to related businesses based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, institutional ownership and valuation.

Earnings & Valuation

This table compares C4 Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
C4 Therapeutics	$35.95 million	-$104.99 million	-4.17
C4 Therapeutics Competitors	$729.47 million	$11.46 million	-14.85

C4 Therapeutics’ rivals have higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

C4 Therapeutics has a beta of 3.16, meaning that its share price is 216% more volatile than the S&P 500. Comparatively, C4 Therapeutics’ rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for C4 Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	1	5	0	2.57
C4 Therapeutics Competitors	9905	15274	45603	1595	2.54

C4 Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 183.33%. As a group, “Biotechnology” companies have a potential upside of 99.37%. Given C4 Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than its rivals.

Profitability

This table compares C4 Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-282.22%	-37.71%	-26.42%
C4 Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Insider & Institutional Ownership

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

C4 Therapeutics beats its rivals on 9 of the 13 factors compared.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity. C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.